DNDN - Dendreon Corporation

Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may improve cancer treatment options for patients. The Companys product portfolio includes active cellular immunotherapy and small molecule product candidates to treat a range of cancers. Its advanced product candidate is Provenge (sipuleucel-T), an active cellular immunotherapy that has completed three Phase III trials for the treatment of metastatic, castrate-resistant, (also known as androgen-independent or hormone-refractory) prostate cancer. Its lead product candidate, Provenge (sipuleucel-T), is designed to target the prostate cancer antigen prostatic acid phosphatase (PAP), an antigen that is expressed in more than 90 % of all prostate cancers. The antigen target for Neuvengetm (lapuleucel-T), its active immunotherapy candidate in development for the treatment of bladder, breast, ovarian and other solid tumors, is a HER2/neu.